(Q34117185)

31 July 2017

1 reference

title

Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours (English)

1 reference

31 July 2017

Slooter GD

1

1 reference

31 July 2017

Mearadji A

2

1 reference

31 July 2017

Breeman WA

3

1 reference

31 July 2017

Marquet RL

4

1 reference

31 July 2017

de Jong M

5

1 reference

31 July 2017

Krenning EP

6

1 reference

31 July 2017

van Eijck CH

7

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

British Journal of Surgery

31 July 2017

published in

1 reference

31 July 2017

volume

88

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

31-40

1 reference

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Endogenous somatostatin and the gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Somatostatin (second of two parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Somatostatin receptors in normal and tumoral tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Molecular pharmacology of somatostatin receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Somatostatin-receptor scintigraphy in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

The diagnostic utility of somatostatin receptor scintigraphy in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Medical treatment of neuroendocrine gut and pancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Long-term treatment with octreotide in patients with the Zollinger-Ellison syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Somatostatin analogue treatment of neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Role of octreotide and somatostatin in the treatment of intestinal fistulae

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Management of digestive tract fistulas. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Role of octreotide in the prevention of postoperative complications following pancreatic resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Somatostatin or octreotide in acute variceal bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Somatostatin analogs for diagnosis and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Somatostatin and the immune and haematopoetic system; a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Direct inhibitory effects of a somatostatin analog, SMS 201-995, on AR4-2J cell proliferation via pertussis toxin-sensitive guanosine triphosphate-binding protein-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Selective suppression of insulin-induced proliferation of cultured human hepatoma cells by somatostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Molecular mechanisms of antiproliferative effect of somatostatin: involvement of a tyrosine phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Gallstones during octreotide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Radiation spectra for Auger-electron emitting radionuclides: report No. 2 of AAPM Nuclear Medicine Task Group No. 6

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Merrill C. Sosman Lecture. The Auger process: a therapeutic promise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Induction of a negative autocrine loop by expression of sst2 somatostatin receptor in NIH 3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

Somatostatin Receptor Scintigraphy for Early Detection of Regional and Distant Metastases of Medullary Carcinoma of the Thyroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2168.2001.01644.X

10.1046/J.1365-2168.2001.01644.X

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference